D. Attachment 1 - Purchase Description - 200g synthesis_FINAL.pdf
PDF 1 MB Posted
- Solicitation number
- 75N95023Q00134
View the file
Other files
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Please wait...
If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.
For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Purchase Description Statement of Need and Purpose:
Background Information and Objective:
Generic Name of Product:
Purchase Description:
Salient Characteristics:
Quantity:
Delivery Date:
Period of Performance:
Option(s):
9.0.0.2.20101008.1.734229
| ResetButton1: |
| SaveAs: |
| Include a general narrative of the need of the requirement and the desired results.: In order to evaluate NCGC00413972 as a preclinical candidate, we will need to have enough of it to carry out the various biological assays and tests needed to make the proper evaluation. This compound has especially shown great promise as an antipancreatic cancer agent in the kpc mouse model of pancreatic cancer. |
| Include a brief history of the requirement, the importance of the requirement, and the overall program objectives.: Pancreatic cancer is one of the deadliest cancers whose survival rates are one of the lowest of all of the different types of cancer. Using NCGC00413972, a compound discovered at NCATS, we would like to evaluate it as a possible treatment for pancreatic cancer therapy |
| Specify the generic name of the component or system, e.g., freezer, microscope, cell sorter, etc.: N-(3-(2-oxopyrrolidin-1-yl)propyl)-4-(6-phenylimidazo[1,5-a]pyrazin-3-yl)benzamide, (Quotation No.) KBQ230104 RC. SMILES string: O=C(NCCCN1CCCC1=O)C(C=C2)=CC=C2C3=NC=C(C=N4)N3C=C4C5=CC=CC=C5 |
| Specify 1) trade name; 2) product’s brand name; 3) manufacturer's name; 4) model, type, catalog, and/or part number(s.): 200g of N-(3-(2-oxopyrrolidin-1-yl)propyl)-4-(6-phenylimidazo[1,5-a]pyrazin-3-yl)benzamide, greater than 95% purity by LCMS and NMR |
| Specify the significant, essential physical, functional, performance, or material element(s) (the distinguishing characteristic) of a product, system, component, or service required. Specify the functions that a system or component must perform to meet the Government’s objectives. Include required levels of performance, features or characteristics of the system or component that are essential to meet the government’s objectives. Specify the Government’s minimum acceptable standards.: Synthesize 200g of final product with 95% purity by LCMS and NMR. |
| Specify quantity. : 200g |
| Specify desired delivery date after receipt of order (30-60 days.): Two months after receipt of order. |
| Specify period of performance for software license, warranty, or maintenance agreements.: 60 days |
| Specify if options for additional quantities or options to extend the term of the contract for service agreements.: N/A |
File details come from the government source that posted it. Updated .